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scaly plaques on the upper back.
Fig 2. A punch biopsy of the skin shows dermal perivas-
cular lymphohistiocytic inflammation with rare eosinophils.
(Hematoxylin-eosin; original magnification:310.)
Abbreviation used:
OCP: oral contraceptive pillCASE REPORT
A 20-year-old woman presented with a 6-year
history of recurrent erythematous papules and
plaques on the trunk. The eruption recurred
cyclically, beginning 5 days before menses and
resolving 1 to 2 days after the menstrual period.
The lesions were asymptomatic, and there were
no associated systemic symptoms. She had not
previously sought treatment. Her medical history
was unremarkable, and she was not taking any
medications.
Examination found widespread erythematous
and edematous papules and nonscaly plaques, on
the chest, back, and lower neck (Fig 1). Lesions were
uniform in color, ranging in size from 3mm to 4 cm in
diameter. A biopsy specimen was taken for histo-
pathologic evaluation (Fig 2).
Results of a punch biopsy of the skin showed
dermal perivascular lymphohistiocytic inflammation,
with rare eosinophils. An intradermal progesterone
test read at 20 minutes was positive (progesterone,
50 mg/mL at a dilution of 1:10 in aqueous solution
elicited a 10-mm wheal vs a 4-mm wheal for the
glycerine control).
The patient was started on levonorgestrel/
ethinyl estradiol, 0.1 mg to 20 g daily. There
was a marked reduction in the number of lesions
during her next menstrual period. By the third
menstrual cycle, after beginning oral contracep-
tive pills (OCPs), no lesions appeared perimenst-
rually. The patient remained clear for another
4 months while taking Levonorgestrel/Ethinyl
Estradiol 0.1 mg to 20 g. She then discontinued
treatment because of the loss of health insurance.
Despite discontinuing OCPs, lesions have not
returned in the 8 months since the medication
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Autoimmune progesterone dermatitis is a rare
cyclic reaction to progesterone that occurs during
the luteal phase of the menstrual cycle.1 The mostJAAD Case Reports 2015;1:319-20.
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320 Fourniercommon cutaneous manifestations are urticaria,
eczematous eruptions, and erythema multiformelike
lesions, although morbilliform, vesiculobullous, and
oral lesions have also been reported.1 There are no
distinguishing histologic features of autoimmune
progesterone dermatitis.2
The earliest cases of autoimmune progesterone
dermatitis appear at menarche, and some patients
have autoimmune progesterone dermatitis that ap-
pears to be triggered by hormonal therapy or
pregnancy.1 Although pregnancy can trigger the
eruption or exacerbate the dermatosis, a subset of
patients with autoimmune progesterone dermatitis
improves during pregnancy, possibly because of
desensitization resulting from persistently elevated
progesterone levels.3
Although the diagnosis can be made clinically, an
intradermal progesterone test can confirm the diag-
nosis. With regard to the intradermal injection, pro-
gesterone in an aqueous suspension is the preferred
modality, as the oil suspension can irritate the skin
and lead to a false-positive result.1
Various treatments are used for autoimmune pro-
gesterone dermatitis, andmost are aimed at suppress-
ing ovulation. OCPs are the most commonly used
therapy.4 This case report suggests that even a short
course of OCPs can provide long-lasting clearance of
lesions, possibly because of the desensitization toprogesterone. Although this patient remains clear of
lesions 8 months after discontinuing OCPs, we will
continue to monitor her to determine if clearance is
lasting. Danazol (prophylactic monthly dosing) has
also been reported to be effective in some patients.1
Although gonadotropin-releasing hormone analogs
have been used to treat autoimmune progesterone
dermatitis, as administration inhibits ovulation and
decreases sex hormone production, they should not
be used for longer than 6 months because of negative
effects on bone metabolism and the cardiovascular
system.2 In refractory cases, bilateral oophorectomy
has been used as a last resort and provides a definitive
treatment.5REFERENCES
1. Herzberg AJ, Strohmeyer CR, Cirillo-Hyland VA. Autoimmune
Progesterone Dermatitis. J Am Acad Dermatol. 1995;32(2Pt 2):
333-338.
2. Vasconcelos C, Xavier P, Vieira AP. Autoimmune Progesterone
Urticaria. Gynecol Endocrinol. 2000;14:245-247.
3. George R, Badawy S. Autoimmune Progesterone Derma-
titis: A Case Report. Case Rep Obstet Gynecol. 2012;2012:
757854.
4. Poffet F, Abraham S, Taramarcaz P. Autoimmune Progesterone
Dermatitis: Potential Role of Cuaneous Angiogenin Expression.
Dermatology. 2011;223:32-35.
5. Rodenas JM, Herranz MT, Tercedor J. Autoimmune progester-
one dermatitis: treatment with oophrectomy. Br J Dermatol.
1998;139:508-511.
